Scarica l'app Stockscreener
31.06
0.64%
-0.20
Pre-mercato:
31.46
0.40
+1.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.26
Aprire:
$29.31
Volume 24 ore:
5.17M
Relative Volume:
5.55
Capitalizzazione di mercato:
$2.07B
Reddito:
$1.55M
Utile/perdita netta:
$-258.76M
Rapporto P/E:
-7.9737
EPS:
-3.8953
Flusso di cassa netto:
$-213.66M
1 W Prestazione:
-2.17%
1M Prestazione:
+3.53%
6M Prestazione:
+20.15%
1 anno Prestazione:
+78.71%
Intervallo 1D:
$28.41
$31.39
Intervallo di 1 settimana:
$28.41
$32.61
Portata 52W:
$14.40
$34.52
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
31.06 | 2.07B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-13 | Iniziato | Barclays | Underweight |
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics announces public offering of common stock - MSN
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics, Inc. (CLDX) Options Chain - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Sahm
Celldex Therapeutics stock falls on equity offering - Investing.com
Celldex prices $300 million stock offering at $29 per share By Investing.com - Investing.com Australia
Celldex Therapeutics offers 10,345,000 shares of common stockSEC filing - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Celldex shares plunge after dumping $300 million stock deal - GuruFocus
Celldex Therapeutics stock falls on equity offering By Investing.com - Investing.com India
Celldex Announces Major Underwritten Public Equity Offering - TipRanks
Celldex Therapeutics Inc (TCE2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering - TradingView
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale - Stock Titan
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Yahoo Finance
Celldex launches public offering of common stock By Investing.com - za.investing.com
Celldex Therapeutics Inc (TCE2.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Announces $300 Million Public Stock Offering - National Today
Celldex Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Celldex prices $300 million stock offering at $29 per share - Investing.com
Celldex lines up $300M for drug launch prep and pipeline work - Stock Titan
Celldex announces pricing of $300 million public offering of common stock - marketscreener.com
Celldex announces proposed public offering of common stock - marketscreener.com
Celldex Announces Proposed Public Offering of Common Stock - bitget.com
Celldex Therapeutics (NASDAQ: CLDX) files prospectus supplement for common stock offering - Stock Titan
Celldex turns to stock sale to fund drug launch prep and pipeline - Stock Titan
CLDX PE Ratio & Valuation, Is CLDX Overvalued - Intellectia AI
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Earnings Report: What makes Celldex Therapeutics Inc stock attractive today2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Portfolio Recap: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum - simplywall.st
Will Celldex Therapeutics Inc stock hit new highs in YEARQuarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Celldex Therapeutics presents positive phase 2 data for barzolvolimab in CSU, ColdU, and SD - marketscreener.com
Celldex reports quality of life gains in urticaria trials - Investing.com
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - Yahoo Finance
Celldex reports quality of life gains in urticaria trials By Investing.com - Investing.com Canada
Vanguard discloses 0 ownership in Celldex (CLDX) after realignment - stocktitan.net
Will Celldex Therapeutics Inc benefit from government policy2026 Risk Factors & High Accuracy Buy Signal Tips - baoquankhu1.vn
Mizuho Initiates Coverage of Celldex Therapeutics (CLDX) with Outperform Recommendation - MSN
Celldex Therapeutics stock hits 52-week high at 32.8 USD By Investing.com - Investing.com Australia
Celldex Therapeutics stock gains after analyst upgrade By Investing.com - Investing.com South Africa
Celldex Therapeutics stock gains after analyst upgrade - Investing.com
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):